Capital raised by Newleos Therapeutics
1 Form D filing · first filed Feb 2025 · Boston, MA
Executive Officer
Listed on Newleos Therapeutics's Form D filings
Robert Hadfield is on file as Executive Officer at Newleos Therapeutics in Boston, MA. Newleos Therapeutics has 1 Form D filing on record, $93.4M raised in total.
NTX-1955 is a groundbreaking GABA A -γ1 selective positive allosteric modulator that represents the company's lead clinical program aimed at treating anxiety disorders. This molecule is designed to help mitigate anxiety symptoms with potentially fewer side effects compared to traditional therapies.